#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow https://t.co/G1MyQDMhOa

Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO

Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22 @rheumnow #myositis https://t.co/pPLcsFLtG9

Consensus for CA screening in IIM Presented: Risk factors to consider screening #Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS

Risk stratification for cancer in myositis @RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c

Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors @RheumNow #ACR22 #Plenary https://t.co/B0eASeo8hG

Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless! It's not flashy but it winds up being the backbone/foundation for many subsequent studies Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD #ACR22 @RheumNow https://t.co/64z7DBFCnX

GUSTO 1y follow-up (TCZ +IVMPx3 but no ongoing PNL in new GCA): initial 24w results disappointing (permanent visual loss x1) BUT follow-up at 2y: control overwhelmingly maintained in responders We need to keep asking: can we use less PNL in GCA? When? ABST0470 #ACR22 @RheumNow https://t.co/smyw2nykO5 https://t.co/d2at0pJlSB

• https://twitter.com/drdavidliew/status/1325906973540315136

Xeljanz in PsA (@pfizer funded) #ACR22 @RheumNow ⚠️safety data -Pancytopenia -Transaminitis -Dyslipidemia -Elevated CPK without #myositis -Avoid in pregnancy and GI strictures 🤰Stop JAKi at least one month prior to conception🤰

#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu

Abst#0001 MIRROR RCT at #ACR22 #plenary Pts with gout on #pegloticase and #gout sustained higher urate lowering response in pts cotreated with #MTX benefit beyond 6 months @rheumnow https://t.co/rTZ3fPaFJS

Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow -Included patients with at least bilateral grade 2 SI or grade 3/4 unilateral SI -5mg BID Xeljanz -Significantly more patients had ASAS20/40 response, CRP reduction, & QOL, vs. placebo -Onset of action noticed at 2 weeks https://t.co/DisKpgR0pt

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content chosen by RheumNow & its Faculty

#ACR22 Abstr#0127. Cross-sectional study of 59 patients with #SAPHO and Chronic Nonbacterial Osteomyelitis showed that patients had high level of pain and fatigue and low function. Important to assess for these and could be a treatment target @RheumNow https://t.co/451KrlJWZF

mTORC1 may be driver of inflammation that connects the pathogenesis of sJIA and MAS as seen in mouse models. Further evaluation needs to be determined in humans, but interesting nonetheless. Abs 0004 #ACR22 @RheumNow https://t.co/RFokZqFQZp https://t.co/E7yxCPDGCd

• mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activati…